Genelux Corporation Names Jason Litten, M.D., as Chief Medical Officer

Genelux Corporation has recently appointed Jason Litten, M.D., as its Chief Medical Officer, effective January 2, 2026. Dr. Litten’s role will involve overseeing the clinical development and medical strategy of Olvi-Vec, a product the company is advancing through various crucial milestones. Genelux’s President, CEO, and Chairman of the Board, Thomas Zindrick, expressed enthusiasm for Dr. Litten’s appointment, highlighting his strategic clinical development approach and dedication to enhancing patient outcomes. Dr. Litten’s vast experience in oncology drug development, including leading intricate programs from early stages to late-stage trials, was noted as a valuable asset to Genelux.

Dr. Litten boasts over 20 years of experience in the biopharmaceutical industry, having worked across academia, large pharmaceutical companies, and innovative biotechnology firms. His expertise in designing, executing, and interpreting Phase 1-4 clinical trials in both liquid and solid tumors expands across various types of therapies, including biologics, small molecules, and cellular therapies. Prior to joining Genelux, Dr. Litten held positions as Chief Medical Officer at Chimeric Therapeutics, Ltd., and Artiva Biotherapeutics, Inc., where he was instrumental in advancing cell therapy programs for various cancers.

Having graduated with an M.D. from Emory University School of Medicine and a B.S. in Finance and Economics from Cornell University, Dr. Litten is well-qualified for his new role. His postdoctoral training in Pediatric Hematology & Oncology at the University of Texas Southwestern Medical Center at Dallas, alongside his licensure as a physician and surgeon in California, further solidify his credentials. Dr. Litten himself expressed his excitement at joining Genelux at a significant juncture, praising Olvi-Vec’s potential in treating multiple tumor types and affirming his commitment to developing clinical strategies that will benefit patients facing challenging cancers.

In recognition of his appointment, Dr. Litten received an inducement award of a stock option to purchase 275,000 shares of common stock under Genelux’s 2023 Inducement Plan. This award, granted in accordance with Nasdaq Listing Rule 5635(c)(4), is set to vest over four years, subject to Dr. Litten’s continued service with the company. Genelux’s focus on developing next-generation oncolytic immunotherapies for aggressive and hard-to-treat solid tumors, exemplified by Olvi-Vec, underscores its commitment to fulfilling unmet medical needs. The company is currently evaluating Olvi-Vec in various clinical trials targeting ovarian and lung cancer, among others, with a view to bringing innovative treatment options to patients.